Altered sensitivity of aspirin-acetylated prostaglandin G/H synthase-2 to inhibition by nonsteroidal anti-inflammatory drugs

Molecular Pharmacology

Volumn 51, Issue 1, 1997, Pages 52-60

  Mancini, Joseph A ^a   Vickers, Philip J ^b   O'Neill, Gary P ^a   Boily, Catherine ^a   Falgueyret, Jean Pierre ^a   Riendeau, Denis ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYICOSATETRAENOIC ACID; ACETYLSALICYLIC ACID; ARACHIDONIC ACID; DICLOFENAC; FLURBIPROFEN; INDOMETACIN; KETOPROFEN; MECLOFENAMIC ACID; METHIONINE; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXIDASE; PROSTAGLANDIN; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; SERINE; SULINDAC SULFIDE;

ACETYLATION; ANIMAL CELL; ARTICLE; CERCOPITHECIDAE; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; IMMUNOBLOTTING; INSECT; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; RADIOIMMUNOASSAY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SPECTROPHOTOMETRY;

EID: 0031022992     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.51.1.52     Document Type: Article

References (41)

1. Vane, J., and R. Botting. Inflammation and the mechanism of action of anti-inflammatory drugs. FASEB J. 1:89-96 (1987).
2. Vane, J. R., and R. M. Botting. New insights into the mode of action of anti-inflammatory drugs. Inflamm. Res. 44:1-10 (1995).
3. Herschman, H. R. Prostaglandin synthase 2. Biochim. Biophys. Acta. 1299:125-140 (1996).
4. Smith, W. L., and L. J. Marnett. Prostaglandin endoperoxide synthase: structure and catalysis. Biochim. Biophys. Acta. 1083:1-17 (1990).
5. Smith, W. L., and D. L. DeWitt. Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Semin. Nephrol. 15:179-194 (1995).
6. Hla, T., and K. Neilson. Human cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. USA 89:7384-7388 (1992).
7. Meade, E. A., W. L. Smith, and D. L. DeWitt. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 268: 6610-6614 (1993).
8. O'Neill, G. P., J. A. Mancini, S. Kargman, J. Yergey, M. Y. Kwan, J.-P. Falgueyret, M. Abramovitz, B. P. Kennedy, M. Ouellet, W. Cromlish, S. Culp, J. F. Evans, A. W. Ford-Hutchinson, and P. J. Vickers. Overexpression of prostaglandin G/H synthases-1 and -2 by recombinant vaccinia virus: inhibition by nonsteroidal anti-inflammatory drugs and biosynthesis of 15-hydroxyeicosatetraenoic acid. Mol. Pharmacol. 45:245-254 (1994).
9. Mitchell, J. A., P. Akarasereenont, C. Thiemermann, R. J. Flower, and J. R. Vane. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. Sci. USA 90:11693-11697 (1994).
10. Gierse, J. K., S. D. Hauser, D. P. Creely, C. Koboldt, S. H. Rangwala, P. C. Isakson, and K. Seibert. Expression and selective inhibition of the constitutive and inducible forms of human cyclooxygenase. Biochem. J. 305:479-484 (1995).
11. Copeland, R. A., J. M. Williams, J. Giannaras, S. Nurnberg, M. Covington, D. Pinto, S. Pick, and J. M. Trzaskos. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc. Natl. Acad. Sci. USA 91:11202-11206 (1994).
12. Battistini, B., R. Botting, and Y. S. Bakhle. COX-1 and COX-2: Toward the development of more selective NSAIDs. Drug News Perspect. 7:501-512 (1994).
13. Laneuville, O., D. K. Breuer, D. L. DeWitt, T. Hla, C. Funk, and W. L. Smith. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by non-steroidal anti-inflammatory drugs. J. Pharmacol. Exp. Ther. 271:927-934 (1995).
14. Barnett, J., J. Chow, D. Ives, M. Chiou, R. Mackenzie, E. Osen, B. Nguyen, S. Tsing, C. Bach, J. Freire, H. Chan, E. Sigal, and C. Ramesha. Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system. Biochim. Biophys. Acta. 1209:130-139 (1994).
15. Masferrer, J. L., B. S. Zweifel, P. T. Manning, S. D. Hauser, K. M. Leahy, W. G. Smith, P. C. Isakson, and K. Seibert. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc. Natl. Acad. Sci. USA 91:3228-3232 (1994).
16. Seibert, K., Y. Zhang, K. Leahy, S. Hauser, J. Masferrer, W. Perkins, L. Lee, and P. Isakson. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc. Natl. Acad. Sci. USA 91:12013-12017 (1994).
17. Chan, C. -C., S. Boyce, C. Brideau, A. W. Ford-Hutchinson, R. Gordon, D. Guay, R. Hill, C. -S. Li, J. Mancini, M. Penneton, P. Prasit, R. Rasori, D. Riendeau, P. Roy, P. Tagari, P. Vickers, E. Wong, and I. W. Rodger. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: A novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J. Pharmacol. Exp. Ther. 274:1531-1537 (1996).
18. Futaki, N., S. Takahashi, M. Yokoyama, I. Arai, S., Higuchi, and S. Otomo. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 47:55-59 (1994).
19. Futaki, N., K. Yoshikawa, Y. Hamasaka, I. Arai, S. Higuchi, H. Iizuka, and S. Otomo. NS-398, a novel anti-inflammatory agent drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen. Pharmacol. 24:105-110 (1993).
20. Gans, K. R., W. Galbraith, R. J. Roman, S. B. Haber, J. S. Kerr, W. K. Schmidt, C. Smith, W. E. Hewes, and N. R. Ackerman. Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J. Pharmacol. Exp. Ther. 254:180-187 (1990).
21. Ouellet, M., and M. D. Percival. Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem. J. 306:247-251 (1995).
22. Shimokawa, T., and W. L. Smith. Prostaglandin endoperoxide synthase. J. Biol. Chem. 267:12387-12392 (1992).
23. Mancini, J. A., G. P. O'Neill, C. Bayly, and P. Vickers. Mutation of Ser-516 in human prostaglandin G/H synthase-2 to methionine or aspirin acetylation of this residue stimulates 15-R-HETE synthesis. FEBS Lett. 342: 33-37 (1994).
24. Lecomte, M., O. Laneuville, C. Ji, D. L. DeWitt, and W. L. Smith. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J. Biol. Chem. 269:13207-13215 (1994).
25. 2 synthase. Nat. Struct. Biol. 2:637-643 (1995).
26. Holtzman, M. J., J. Turk, and L. P. Shornick. Identification of a pharmacologically distinct prostaglandin H synthase in cultured epithelial cells. J. Biol. Chem. 267:21438-21445 (1992).
27. Claria, J., and C. N. Serhan. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc. Natl. Acad. Sci. USA 92:9475-9479 (1995).
28. Takata, S., A. Papayianni, M. Matsubara, W. Jimenez, P. H. Pronovost, and H. R. Brady. 15-hydroxyeicosatetraenoic acid inhibits neutrophil migration across cytokine-activated endothelium. Am. J. Pathol. 145:541-549 (1994).
29. Wennogle, L. P., H. Liang, J. C. Quintavalla, B. R. Bowen, J. Wasvary, D. B. Miller, A. Allentoff, W. Boyer, M. Kelly, and P. Marshall. Comparison of recombinant cyclooxygenase-2 to native isoforms: aspirin labeling of the active site. FEBS Lett. 371:315-320 (1995).
30. Picot, D., P. J. Loll, and R. M. Garavito. The X-ray crystal structure of the membrane protein prostaglandin synthase-1. Nature (Lond.) 367:243-249 (1994).
31. Loll, P. J., and R. M. Garavito. The isoforms of cyclooxygenase: structure and function. Expert Opin. Invest. Drugs 3:1171-1180 (1994).
32. Cromlish, W. A., P. Payette, S. A. Culp, M. Ouellet, M. D. Percival, and B. P. Kennedy. High level expression of active human cyclooxygenase-2 in insect cells. Arch. Biochem. Biophys. 315:111-118 (1994).
33. Mancini, J. A., D. Riendeau, J. -P. Falgueyret, P. J. Vickers, and G. P. O'Neill. Arginine 120 of prostaglandin G/H synthase-1 is required for the inhibition by nonsteroidal anti-inflammatory drugs containing a carboxylic acid moiety. J. Biol. Chem. 270:29372-29377 (1995).
34. Percival, M. D., M. Ouellet, C. Vincent, J. Yergey, B. P. Kennedy, and G. P. O'Neill. Purification and characterization of recombinant human cyclooxygenase-2. Arch. Biochem. Biophys. 315:111-118 (1994).
35. Gann, P. H., J. E. Manson, R. J. Glynn, J. E. Buring, and C. H. Hennekens. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J. Natl. Canc. Inst. 85:1220-1224 (1993).
36. Peleg, I. I, H. T. Maibach, S. H. Brown, and M. Wilcox. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch. Intern. Med. 154:394-399 (1994).
37. Bhattacharyya, D. K., M. Lecomte, C. J. Rieke, R. M. Garavito, and W. L. Smith. Involvement of arginine 120, glutamate 524, and tyrosine 355 in the binding of arachidonate and 2-phenylpropionic acid inhibitors to the cyclooxygenase active site of ovine prostaglandin endoperoxide H synthase-1. J. Biol. Chem. 271:2179-21844 (1996).
38. Shimokawa, T., R. J. Kulmacz, D. L. DeWitt, and W. L. Smith. Tyrosine 385 of prostaglandin endoperoxide synthase is required for cyclooxygenase catalysis. J. Biol. Chem. 265:20073-20076 (1990).
39. Markey, C. M., A. Alward, P. E. Weller, and L. J. Marnett. Quantitative studies of hydroperoxide reduction by prostaglandin H synthase: reducing substrate specificity and the relationship of peroxidase to cyclooxygenase activities. J. Biol. Chem. 262:6266-6279 (1987).
40. Kaever, V., M. Goppelt-Strube, and K. Resch. Enhancement of eicosanoid synthesis in mouse peritoneal macrophages by the organic mercury compound thimerosal. Prostaglandins 35:885-902 (1988).
41. Kargman, S., G. P. O'Neill, P. J. Vickers, J. F. Evans, J. A. Mancini, and S. Jothy. Expression of prostaglandin G/H synthase-1 and -2 in human colon cancer. Cancer Res. 55:2556-2559 (1995).